logo
logo

Adc Therapeutics Announces $175 Million Senior Secured Term Loan From Owl Rock And Oaktree And Settlement Of Existing Senior Secured Convertible Notes

Adc Therapeutics Announces $175 Million Senior Secured Term Loan From Owl Rock And Oaktree And Settlement Of Existing Senior Secured Convertible Notes

08/15/22, 8:36 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/CH.svglausanne
Money raised
$175 million
Industry
therapeutics
biotechnology
health care
ADC Therapeutics SA (NYSE: ADCT) today announced that it has completed a series of strategic transactions in which it:

Company Info

Company
ADC Therapeutics
Location
fashion island boulevard
lausanne, vaud, switzerland
Additional Info
ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn. ZYNLONTA® is a registered trademark of ADC Therapeutics SA.

Related People